24-valent pneumococcal conjugate vaccine
Vaccineexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2022 (NCT05266456)
Timeline
Indications
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300644 | Phase 2 | Nov 25, 2025 | China National Pharmaceutical Group |
| NCT06800261 | Phase 1 | Apr 30, 2025 | China National Pharmaceutical Group, Government of China |
| NCT06550830 | Phase 1 | Aug 28, 2024 | China National Pharmaceutical Group, Government of China |
| NCT06474377 | Phase 1 | Jun 20, 2024 | China National Pharmaceutical Group, Government of China |
| NCT06675032 | Phase 1 | Apr 27, 2024 | Government of China |
| NCT06678620 | Phase 2 | Apr 20, 2024 | Government of China |
| NCT06678607 | Phase 1 | Nov 19, 2023 | Government of China |
| NCT07025876 | Early Phase 1 (Phase 1) | Nov 18, 2023 | Government of China |
| NCT05844423 | Phase 2 | Mar 29, 2023 | Vaxcyte, Inc. |
| NCT05297578 | Phase 2 | Jun 15, 2022 | Vaxcyte, Inc. |
| NCT05266456 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2022 | Vaxcyte, Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 7 | 4 | 2 | 2023 |
| China National Pharmaceutical Group | For profit | 4 | 4 | 2 | 2024 |
| Vaxcyte, Inc. | For profit | 3 | 3 | 1 | 2022 |
3 organizations
Page 1 / 1